Forecasting The Future: 8 Analyst Projections For IQVIA Hldgs


Across the recent three months, 8 analysts have shared their insights on IQVIA Hldgs IQV, expressing a variety of opinions spanning from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 3 2 0 0
Last 30D 0 0 1 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 3 3 1 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $274.75, a high estimate of $300.00, and a low estimate of $245.00. This current average reflects an increase of 8.38% from the previous average price target of $253.50.

Diving into Analyst Ratings: An In-Depth Exploration

The perception of IQVIA Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Eric Coldwell Baird Lowers Neutral $245.00 $254.00
Jailendra Singh Truist Securities Raises Buy $297.00 $286.00
Michael Cherny Leerink Partners Announces Outperform $290.00 -
Elizabeth Anderson Evercore ISI Group Raises Market Outperform $265.00 $255.00
Dan Brennan UBS Raises Buy $300.00 $240.00
Eric Coldwell Baird Raises Neutral $251.00 $226.00
Luke Sergott Barclays Raises Overweight $265.00 $260.00
David Larsen BTIG Announces Buy $285.00 -

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IQVIA Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IQVIA Hldgs compared to the broader market.
  • Price Targets: Analysts provide insights into price targets, offering estimates for the future value of IQVIA Hldgs's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into IQVIA Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on IQVIA Hldgs analyst ratings.

Delving into IQVIA Hldgs's Background

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Hldgs's Financial Performance

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: IQVIA Hldgs's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 3.45%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: IQVIA Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 12.13%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): IQVIA Hldgs's ROE excels beyond industry benchmarks, reaching 7.87%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): IQVIA Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.78% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: IQVIA Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.27, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

The Basics of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!